ÂÜÀòÂÒÂ×

Jennifer Willoughby, PhD, is an accomplished Associate Director and Medical Science Liaison at Alnylam Pharmaceuticals, specializing in ultra-rare diseases such as Acute Hepatic Porphyria and Primary Hyperoxaluria Type 1. With extensive experience in medical communication and scientific collaboration, Jennifer has played a pivotal role in educating healthcare professionals, delivering actionable insights, and contributing to strategic medical initiatives. Jennifer holds a Doctorate in Cellular and Molecular Biology from Boston University and has a strong background in molecular biology research, including work on siRNA therapeutics and the impact of angiogenesis on tumor development. Throughout a career spanning over two decades, Jennifer has demonstrated expertise in scientific communication, clinical strategy, and innovative therapeutic solutions.